Web Exclusives


Breast cancer’s initiation, progression, and behavior may be affected by chronic inflammation. Read More ›

In recently released study results of the phase 2 CodeBreaK 100 trial, sotorasib demonstrated a response rate across all trial subgroups. Read More ›

Lung cancer incidence rates have declined due to a decrease in risk factors and improved screening and treatment. Read More ›

Immune checkpoint inhibitors cause rare severe adverse events in patients, but most patients improve with treatment. Read More ›

Patients with NSCLC harboring KRAS G12C have distinct imaging patterns from patients with other NSCLC genetic mutations. Read More ›

A significant increase in clinical trial accruals resulted from dedicating a single employee to screening patients, suggesting a potential paradigm for limited resource settings. Read More ›

To reduce cancer-related cognitive impairment, there may be a benefit to targeting specific inflammatory processes. Read More ›

Quality of social support may impact patients’ disease understanding and should be considered when creating clinical interventions. Read More ›

Differences in patient characteristics, CDK4/6 inhibitor schedule, treatment duration, and discontinuation rates may contribute to differences in outcomes. Read More ›

Page 10 of 48


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: